Eric Schadt

Last updated
Eric Schadt
Eric Schadt headshot 2014.jpg
Born (1965-01-31) January 31, 1965 (age 58)
St. Joseph, Michigan, United States
Alma mater California Polytechnic State University
University of California, Davis
University of California, Los Angeles
Scientific career
Institutions
Sema4
Icahn School of Medicine at Mount Sinai
Sage Bionetworks

Eric Emil Schadt (born January 31, 1965) is an American mathematician and computational biologist. He is founder and former chief executive officer of Sema4, a patient-centered health intelligence company, and dean for precision medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously founding director of the Icahn Institute for Genomics and Multiscale Biology and chair of the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai.

Contents

Schadt's work combines supercomputing and advanced computational modeling with diverse biological data to understand the relationship between genes, gene products, other molecular features such as cells, organs, organisms, and communities and their impact on complex human traits such as disease. [1] He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology to more accurately model the complexity of biological systems. [2] [3] Schadt has also worked to engage the public, encouraging people to participate in scientific research and helping them understand privacy concerns around DNA-based information. [4] [5]

Research and training

In 1983, Schadt left high school early to enlist in the United States Air Force and joined a Special Operations/Rescue unit. After sustaining a serious shoulder injury that required reconstructive surgery, Schadt attended California Polytechnic State University on a military scholarship to study computer science and mathematics, and received his bachelor's degree in applied mathematics in 1991. [1] He went on to earn a master's degree in pure mathematics at the University of California, Davis in 1993. After that, he pursued a PhD in biomathematics at the University of California, Los Angeles, which required PhD candidacy in both molecular biology and biomathematics, completing his doctorate under the supervision of Ken Lange in 2000. [3] During his PhD work, Schadt worked as a senior software engineer at the UCLA Office of Academic Computing and later as director of computing in the UCLA mathematical sciences department[ citation needed ].

Scientific career

Early career

While completing his PhD, Schadt joined Roche Bioscience in 1998 as a senior research scientist and began his work on DNA microarrays, designing novel algorithms to process and interpret these data. He published some of the first independently developed algorithms to process gene chip data [6] [7] work that he later applied to produce an early whole genome functional annotation of the human genome. [8]

In 1999, after becoming acquainted with Stephen Friend, he was hired as chief scientist at Rosetta Inpharmatics, a startup biotech company focused on the generation and analysis of high-dimensional functional genomics data. [1] Merck acquired Rosetta in 2001, which allowed Schadt to combine large-scale molecular profiling with Merck's disease-focused databases to demonstrate the existence of molecular networks working together to give rise to complex system behavior. [9] [10] During this period Schadt developed his theory that single-gene approaches to understanding and treating common human diseases must give way to a network-based approach and that many of the failures in pharmaceutical therapies were caused by an incomplete understanding of biology underlying the therapeutic targets. [2]

Demonstrating the ability to infer causal relationships among features in high dimensional data using DNA variation information, Schadt and his colleagues at Merck began reconstructing predictive networks that were shown to be causally associated with disease, [11] [12] [13] [14] [15] leading to the idea of targeting networks, not single genes, to effectively treat common disorders such as Alzheimer's disease, obesity, and most forms of cancer. [16] A Merck spokesman said that the papers Schadt began publishing based on this genetic network data “changed the way people looked at disease.” Schadt used the information about these networks to determine which genes Merck should pursue as targets; by the time he left the company, Schadt estimated that his group was responsible for half the drugs in the company's development pipeline. [1]

In 2009, along with Stephen Friend, Schadt founded Sage Bionetworks, [3] a nonprofit organization with the goal of encouraging collaboration between academic and commercial scientists in performing network-based studies of disease and making the data publicly available. When Merck closed down the Rosetta business unit, it donated the data, research, and computer equipment from that unit to Sage Bionetworks. [1] Schadt remains involved as a board member. [17]

Also in 2009, Schadt joined DNA sequencing company Pacific Biosciences as the chief scientific officer. During his time there, Schadt demonstrated the application of SMRT sequencing technology for various applications, [18] including to sequence bacterial genomes of public health concern to provide real-time information about these pathogenic strains during an active outbreak. He led research projects to resolve the origins of the Haitian cholera outbreak strain from 2010 [19] and to characterize the highly virulent German E. coli outbreak strain in the summer of 2011. [20] He also demonstrated the ability to infer epigenetic changes from the sequencing data, uncovering novel regulatory mechanisms that may impact pathogenicity and virulence of bacteria of concern in public health. [21] [22]

Mount Sinai

In 2011, Schadt joined the Mount Sinai School of Medicine in New York, where he founded the new Icahn Institute for Genomics and Multiscale Biology and became chair of the Department of Genetics and Genomics Sciences. [23] [24] [25] The new institute was launched with $100 million for the first five years and is co-directed by Andrew Kasarskis. [25] Schadt has said that his interest in joining Mt. Sinai was to bring predictive modeling of biology to patients. In his time at the institute, he has opened the first CLIA-certified next-generation sequencing lab in New York City [26] and established the first class at the school in which students sequence their own genomes. [27] [28] Schadt also serves on the executive committee of the New York Genome Center.

In 2013, Schadt and his team were awarded a grant from the National Institutes of Health to study biological networks in Alzheimer's disease. [29] They also published a paper in Cell reporting that a network of genes linked to inflammatory response plays a role in late-onset Alzheimer's disease. [30] [31] Also that year, Schadt joined the Cure Alzheimer's Fund's Research Consortium along with Richard L. Huganir.

Schadt's team was cited as the reason the Icahn School of Medicine at Mount Sinai was named #5 of the top 10 most innovative organizations in big data by Fast Company in a 2014 ranking. [32] According to the article, "The New York City hospital is bringing on top Silicon Valley talent to build a facility that will map patients’ genomes to predict diseases, reduce the number of average hospital visits, and streamline electronic medical records."

In May 2014, Schadt and his team announced the Resilience Project in collaboration with Sage Bionetworks. [33] The project intended to perform genotyping on as many as 1 million people to find protective biological mechanisms that prevent disease-causing genetic mutations from becoming active. Participants were to be healthy people age 30 and older, and the project initially targeted variations linked to 127 Mendelian diseases. [34] [35] Based on an analysis of publicly available data, scientists in the Resilience Project estimated that one person in 15,000 has a protective mechanism preventing activity of disease-causing genetic variants. [36] The project led to a paper published in 2016 in Nature Biotechnology, reporting the analysis of nearly 600,000 genomes and the identification of individuals resilient to severe Mendelian childhood diseases.

Sema4

Schadt founded Sema4, "a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights," [37] in June 2017. [38] The company uses Centrellis™, their health analytics platform, to build predictive models of human health and generate personalized medicine insights. [37] Sema4, which was named one of the 150 most promising private digital health companies in the world by CB Insights in its 2020 Digital Health 150 ranking, [39] operates two state-of-the art clinical laboratories in Connecticut, including a 70,000-square-foot facility opened in December 2020 [40] The company announced in February 2021 that it would be going public through a merger with CM Life Sciences, a special purpose acquisition company (SPAC). [41]

Media appearances and awards

Schadt has appeared on CNN, CNBC, BBC, Bloomberg Radio, and Bloomberg TV. [42] He and his scientific projects have been profiled in the New York Times, Esquire magazine, [2] Bloomberg BusinessWeek, [43] among others, [44] and several scientific trade publications. The Huffington Post published a commentary by Schadt, calling on scientists to incorporate information about RNA, proteins, metabolites and more into their genetic or clinical research, while asking the public to participate in research projects to help speed scientific discovery. [45] Schadt has also spoken at numerous events including TEDMED, the health/medicine edition of the world-famous TED conference.

He has received many awards, including the Thomson Reuters World's Most Influential Scientific Minds Award [46] and the Merck Presidential Fellowship Award. He was executive producer and creative director of a documentary film called “The New Biology” that won a Cine Master Series Award in 2012. [47] In 2020, Schadt was named the BioCT Entrepreneur of the Year. [48]

Selected publications

Schadt has published more than 370 peer-reviewed papers. [49] He is a highly cited author, with an h-index of 129 and more than 145,500 citations. [50] Some notable publications include:

Related Research Articles

<span class="mw-page-title-main">Bioinformatics</span> Computational analysis of large, complex sets of biological data

Bioinformatics is an interdisciplinary field of science that develops methods and software tools for understanding biological data, especially when the data sets are large and complex. Bioinformatics uses biology, chemistry, physics, computer science, computer programming, information engineering, mathematics and statistics to analyze and interpret biological data. The subsequent process of analyzing and interpreting data is referred to as computational biology.

<span class="mw-page-title-main">Genomics</span> Discipline in genetics

Genomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.

<span class="mw-page-title-main">Leroy Hood</span> American biologist (born 1938)

Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA.

Samuel E. Gandy, is a neurologist, cell biologist, Alzheimer's disease (AD) researcher and expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. His team discovered the first drugs that could lower the formation of amyloid.

<span class="mw-page-title-main">Robert J. Desnick</span> American geneticist

Robert J. Desnick is an American human geneticist whose basic and translational research accomplishments include significant discoveries in genomics, pharmacogenetics, gene therapy, personalized medicine, and the treatment of genetic diseases. His translational research has led to the development of the enzyme replacement therapy (ERT) and the chaperone therapy for Fabry disease, ERT for Niemann–Pick disease type B, and the RNA Interference Therapy for the Acute Hepatic Porphyrias.

<span class="mw-page-title-main">Exome sequencing</span> Sequencing of all the exons of a genome

Exome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all of the protein-coding regions of genes in a genome. It consists of two steps: the first step is to select only the subset of DNA that encodes proteins. These regions are known as exons—humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist whose specification is structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.

Sage Bionetworks is a nonprofit organization in Seattle that promotes open science and patient engagement in the research process. It is led by Luca Foschini. It was co-founded by Stephen Friend and Eric Schadt.

The Icahn Genomics Institute is a biomedical and genomics research institute within the Icahn School of Medicine at Mount Sinai in New York City. Its aim is to establish a new generation of medicines that can better treat diseases afflicting the world, including cancer, heart disease and infectious pathogens. To do this, the institute’s doctors and scientists are developing and employing new types of treatments that utilize DNA and RNA based therapies, such as CRISPR, siRNA, RNA vaccines, and CAR T cells, and searching for novel drug targets through the use of functional genomics and data science. The institute is led by Brian Brown, a leading expert in gene therapy, genetic engineering, and molecular immunology.

<span class="mw-page-title-main">Andrew Kasarskis</span> American biologist

Andrew Kasarskis is an American biologist. He is the Chief Data Officer (CDO) at Sema4. He was previously CDO and an Executive Vice President (EVP) at the Mount Sinai Health System in New York City and, before that, vice chair of the Department of Genetics and Genomic Sciences and Co-director of the Icahn Institute for Genomics and Multiscale Biology at the Icahn School of Medicine at Mount Sinai. Kasarskis is known for taking a network-based approach to biology and for directing the first medical school class offering students the opportunity to fully sequence and analyze their own genomes.

Ethylin Wang Jabs is an American physician and scientist with expertise in medical genetics, pediatrics, and craniofacial biology. She is currently vice chair of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai Medical Center. Jabs is also a professor in the departments of developmental and regenerative biology and pediatrics at Mount Sinai and an adjunct professor in pediatrics, medicine, and surgery at the Johns Hopkins School of Medicine. Her research and clinical practice have focused on development genetics and patients with birth defects.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Joel Dudley</span>

Joel Dudley is currently Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. In March, 2018 Dr. Dudley was named Executive Vice President for Precision Health for the Mount Sinai Health System (MSHS). In 2017 he was awarded an Endowed Professorship by Mount Sinai in Biomedical Data Science. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine. His work is focused at the nexus of -omics, digital health, artificial intelligence (AI), scientific wellness, and healthcare delivery. His work has been featured in the Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. He was named in 2014 as one of the 100 most creative people in business by Fast Company magazine. He is co-author of the book Exploring Personal Genomics from Oxford University Press. Dr. Dudley received a BS in Microbiology from Arizona State University and an MS and PhD in Biomedical Informatics from Stanford University School of Medicine.

Phylomedicine is an emerging discipline at the intersection of medicine, genomics, and evolution. It focuses on the use of evolutionary knowledge to predict functional consequences of mutations found in personal genomes and populations.

<span class="mw-page-title-main">Giulio Maria Pasinetti</span>

Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology, Psychiatry, Neuroscience, and Geriatrics and Palliative Medicine at ISMMS.

Elective genetic and genomic testing are DNA tests performed for an individual who does not have an indication for testing. An elective genetic test analyzes selected sites in the human genome while an elective genomic test analyzes the entire human genome. Some elective genetic and genomic tests require a physician to order the test to ensure that individuals understand the risks and benefits of testing as well as the results. Other DNA-based tests, such as a genealogical DNA test do not require a physician's order. Elective testing is generally not paid for by health insurance companies. With the advent of personalized medicine, also called precision medicine, an increasing number of individuals are undertaking elective genetic and genomic testing.

The Resilience Project is a project, undertaken by the Icahn School of Medicine at Mount Sinai in collaboration with Sage Bionetworks.

<span class="mw-page-title-main">Manolis Kellis</span> Greek-born computational biologist

Manolis Kellis is a professor of Computer Science at the Massachusetts Institute of Technology (MIT) in the area of Computational Biology and a member of the Broad Institute of MIT and Harvard. He is the head of the Computational Biology Group at MIT and is a Principal Investigator in the Computer Science and Artificial Intelligence Lab (CSAIL) at MIT.

Alison Mary Goate is a professor of neuroscience and Director of the Loeb Center for Alzheimer's Disease at Icahn School of Medicine at Mount Sinai, New York City. She was previously professor of genetics in psychiatry, professor of genetics, and professor of neurology at Washington University School of Medicine.

Eric R. Gamazon is a statistical geneticist in Vanderbilt University, with faculty affiliations in the Division of Genetic Medicine, Data Science Institute, and Center for Precision Medicine. He is a Life Member of Clare Hall, Cambridge University after election to a Visiting Fellowship (2018).

References

  1. 1 2 3 4 5 David Ewing Duncan (2009-08-24). "Enlisting Computers to Unravel the True Complexity of Disease". The New York Times . Retrieved 2017-06-17.
  2. 1 2 3 Junod, Tom (2011-03-22). "Eric Schadt Profile - Interview with Eric Schadt Pacific Biosciences". Esquire.com. Retrieved 2017-06-17.
  3. 1 2 3 "The Schadt Equation | GEN". Genengnews.com. 2013-01-15. Retrieved 2017-06-17.
  4. 1 2 Schadt EE (2012). "The changing privacy landscape in the era of big data". Molecular Systems Biology. 8: 612. doi:10.1038/msb.2012.47. PMC   3472686 . PMID   22968446.
  5. ↑ ""Genetic Heroes" May Be Key to Treating Debilitating Diseases". Scientific American. 2014-05-30. Retrieved 2017-06-17.
  6. ↑ Schadt, E. E.; Li, C.; Su, C.; Wong, W. H. (2000). "Analyzing high-density oligonucleotide gene expression array data" (PDF). Journal of Cellular Biochemistry. 80 (2): 192–202. doi:10.1002/1097-4644(20010201)80:2<192::aid-jcb50>3.3.co;2-n. PMID   11074587.
  7. ↑ Schadt, E. E.; Li, C.; Su, C.; Wong, W. H. (2001). "Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data" (PDF). Journal of Cellular Biochemistry. Supplement Suppl 37: 120–125. doi:10.1002/jcb.10073. PMID   11842437. S2CID   6810381.
  8. 1 2 Shoemaker, D. D.; et al. (2001). "Experimental annotation of the human genome using microarray technology" (PDF). Nature. 409 (6822): 922–927. Bibcode:2001Natur.409..922S. doi: 10.1038/35057141 . PMID   11237012. S2CID   2509337.
  9. ↑ Schadt, E. E.; et al. (2003). "Genetics of gene expression surveyed in maize, mouse and man". Nature. 422 (6929): 297–302. Bibcode:2003Natur.422..297S. doi:10.1038/nature01434. PMID   12646919. S2CID   2559717.
  10. ↑ Schadt, E. E.; Monks, S. A.; Friend, S. H. (2003). "A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets". Biochemical Society Transactions. 31 (2): 437–443. doi:10.1042/bst0310437. PMID   12653656. Archived from the original on 2013-04-14. Retrieved 2013-01-30.
  11. ↑ Schadt, E. E.; Sachs, A.; Friend, S. (2005). "Embracing complexity, inching closer to reality". Science's STKE. 2005 (295): 40. doi:10.1126/stke.2952005pe40. PMID   16077086. S2CID   23744520.
  12. ↑ Chen, Y.; et al. (2008). "Variations in DNA elucidate molecular networks that cause disease". Nature. 452 (7186): 429–435. Bibcode:2008Natur.452..429C. doi:10.1038/nature06757. PMC   2841398 . PMID   18344982.
  13. ↑ Emilsson, V.; et al. (2008). "Genetics of gene expression and its effect on disease". Nature. 452 (7186): 423–428. Bibcode:2008Natur.452..423E. doi:10.1038/nature06758. PMID   18344981. S2CID   1219108.
  14. ↑ Schadt, E. E. (2009). "Molecular networks as sensors and drivers of common human diseases". Nature. 461 (7261): 218–223. Bibcode:2009Natur.461..218S. doi:10.1038/nature08454. PMID   19741703. S2CID   4323333.
  15. ↑ Yang, X.; et al. (2009). "Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks". Nature Genetics. 41 (4): 415–423. doi:10.1038/ng.325. PMC   2837947 . PMID   19270708.
  16. ↑ Schadt, E. E.; Friend, S. H.; Shaywitz, D. A. (2009). "A network view of disease and compound screening". Nature Reviews Drug Discovery. 8 (4): 286–295. doi:10.1038/nrd2826. PMID   19337271. S2CID   21562023.
  17. ↑ "Sage Bionetworks Seattle | Directors". Archived from the original on 2012-01-27. Retrieved 2013-01-30.
  18. ↑ Schadt, E. E.; Turner, S.; Kasarskis, A. (2010). "A window into third-generation sequencing". Human Molecular Genetics. 19 (R2): R227–R240. doi: 10.1093/hmg/ddq416 . PMID   20858600.
  19. ↑ Chin, C. S.; et al. (2011). "The origin of the Haitian cholera outbreak strain". The New England Journal of Medicine. 364 (1): 33–42. doi:10.1056/NEJMoa1012928. PMC   3030187 . PMID   21142692.
  20. ↑ Rasko, D. A.; et al. (2011). "Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany". The New England Journal of Medicine. 365 (8): 709–717. doi:10.1056/NEJMoa1106920. PMC   3168948 . PMID   21793740.
  21. 1 2 Fang, G.; et al. (2012). "Genome-wide mapping of methylated adenine residues in pathogenic Escherichia coli using single-molecule real-time sequencing". Nature Biotechnology. 30 (12): 1232–1239. doi:10.1038/nbt.2432. PMC   3879109 . PMID   23138224.
  22. ↑ Schadt, E. E.; et al. (2013). "Modeling kinetic rate variation in third generation DNA sequencing data to detect putative modifications to DNA bases". Genome Research. 23 (1): 129–141. doi:10.1101/gr.136739.111. PMC   3530673 . PMID   23093720.
  23. ↑ "Eric Schadt, PhD, Named Director of Institute for Genomics and Multiscale Biology at The Mount Sinai Medical Center - Icahn School of Medicine at Mount Sinai". Mssm.edu. Retrieved 2017-06-17.
  24. ↑ "PacBio CSO Eric Schadt to Lead 'Multiscale Institute' at Mount Sinai - Bio-IT World". Archived from the original on 2011-07-30. Retrieved 2013-01-30.
  25. 1 2 "Eric Schadt of Pacific Biosciences Joins Mount Sinai - NYTimes.com". Archived from the original on 2013-02-24. Retrieved 2013-01-30.
  26. ↑ Schadt, E. (2012). "Eric Schadt". Nature Biotechnology. 30 (8): 769–770. doi: 10.1038/nbt.2331 . PMID   22871721.
  27. ↑ "Q&A: Mount Sinai's Andrew Kasarskis on Teaching Students how to Analyze their Own Genomes". GenomeWeb.com. 2012-10-24. Retrieved 2017-06-17.
  28. ↑ "Genomics annual report fnl by Mount Sinai Health System". Issuu.com. 2014-05-02. Retrieved 2017-06-17.
  29. ↑ "NIH funding boosts new Alzheimer's research on prevention, novel drug targets | National Institutes of Health (NIH)". Nih.gov. 2013-09-18. Retrieved 2017-06-17.
  30. ↑ "Cell - Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer's Disease". www.cell.com. Archived from the original on 13 July 2013. Retrieved 27 January 2022.
  31. ↑ "Gene Studies Could Point to New Alzheimer's Treatments - US News". Archived from the original on 2014-08-19. Retrieved 2014-08-18.
  32. ↑ "The Most Innovative Companies of 2014 by Sector". Fast Company. Retrieved 2017-06-17.
  33. ↑ Friend, Stephen H. (2014-05-30). "Clues from the resilient | Science". Science. 344 (6187): 970–972. doi:10.1126/science.1255648. PMID   24876479. S2CID   26492504 . Retrieved 2017-06-17.
  34. ↑ "The Search for Genes That Prevent Disease". The Atlantic. 2014-05-29. Retrieved 2017-06-17.
  35. ↑ "The Resilience Project | Join the Search. Be a Hero". Resilienceproject.me. 2016-04-11. Retrieved 2017-06-17.
  36. ↑ "Searching For The Hidden Health Heroes Whose DNA Prevents Disease". Fastcoexist.com. 2014-05-29. Retrieved 2017-06-17.
  37. 1 2 "Our Story". Sema4.com. Retrieved 2021-04-12.
  38. ↑ "Introducing Sema4: A Spinout Company of the Mount Sinai Health System | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2021-03-16.
  39. ↑ "Sema4 Named to the 2020 CB Insights Digital Health 150, a List of the Most Innovative Digital Health Startups" . Retrieved 2021-04-20.
  40. ↑ "Sema4 opens 70,000-square-foot clinical lab in Stamford". 3 December 2020. Retrieved 2021-04-12.
  41. ↑ "Sema4 to Go Public Through Merger With Special Purpose Acquisition Company". GenomeWeb. 10 February 2021. Retrieved 2021-03-16.
  42. ↑ "How the iPhone is Helping Doctors Battle Diseases". Bloomberg.com. 11 March 2015.
  43. ↑ "Icahn Institute's Eric Schadt on Data Analysis in Medicine - Bloomberg". Businessweek.com. 2014-03-06. Archived from the original on August 15, 2014. Retrieved 2017-06-17.
  44. ↑ "The little girl who may hold the secret to aging". Macleans.ca. 2014-07-20. Retrieved 2017-06-17.
  45. ↑ "It's Not Just the Genes | HuffPost". Huffingtonpost.com. 24 October 2013. Retrieved 2017-06-17.
  46. ↑ "The World's Most Influential Scientific Minds" (PDF). Sciencewatch.com. 2014. Retrieved 2017-06-17.
  47. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2013-01-20. Retrieved 2013-01-30.{{cite web}}: CS1 maint: archived copy as title (link)
  48. ↑ "Eric Schadt, Founder & CEO of Sema4, Named 2020 BioCT Entrepreneur of the Year" . Retrieved 2021-04-12.
  49. ↑ "schadt, ee - search results". PubMed. Retrieved 2021-04-20.
  50. ↑ "Eric Schadt - Google Scholar" . Retrieved 2021-04-20.
  51. ↑ Schadt, E. E.; et al. (2005). "An integrative genomics approach to infer causal associations between gene expression and disease". Nature Genetics. 37 (7): 710–717. doi:10.1038/ng1589. PMC   2841396 . PMID   15965475.
  52. ↑ + See all authors and affiliations (2005-12-23). "The Runners-Up | Science". Science. 310 (5756): 1880–1885. doi:10.1126/science.310.5756.1880a. PMID   16373539. S2CID   32119689 . Retrieved 2017-06-17.
  53. ↑ Califano A; Butte AJ; Friend S; Ideker T; Schadt EE (2012). "Integrative Network-based Association Studies: Leveraging cell regulatory models in the post-GWAS era". Nature Genetics. 44 (8): 841–847. doi:10.1038/ng.2355. PMC   3593099 . PMID   22836096.
  54. ↑ Peters, L. A.; et al. (2017). "A functional genomics predictive network model identifies regulators of inflammatory bowel disease". Nature Genetics. 49 (10): 1437–1449. doi:10.1038/ng.3947. PMC   5660607 . PMID   28892060.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.